Clinical trials: Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
ZR2 Sequential Immunochemotherapy for Newly Treated MCL
Patients with newly diagnosed MCL were treated with ZR2 regimen for 3 cycles, followed by 3 cycles of immunochemotherapy, and zebrutinib maintenance therapy for 2 years after the end of induction therapy, in order to improve the…
- Trial name
- NCT05992597
- Testing
- ZR2 RDHAP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital